Core Viewpoint - Aktis Oncology, Inc. has received Fast Track designation from the U.S. FDA for its drug AKY-1189, aimed at treating adult patients with locally advanced or metastatic urothelial cancer who have progressed after prior systemic therapies [1][7] Group 1: Fast Track Designation - Fast Track designation is intended to expedite the development and review of drugs for serious conditions, allowing for more frequent interactions with the FDA and the possibility of rolling submissions for Biologics License Applications [2] - The designation provides Aktis Oncology a unique opportunity to collaborate closely with the FDA to expedite the development of AKY-1189, addressing an unmet medical need in urothelial cancer treatment [3] Group 2: Clinical Trials and Development - Aktis is conducting a multi-site Phase 1b clinical trial (NCT07020117) for AKY-1189, which includes patients with locally advanced or metastatic urothelial cancer and other Nectin-4 expressing tumors [3] - Preliminary results from Part 1 of the trial are expected to be presented in the first quarter of 2027 [3] Group 3: Technology and Pipeline - Aktis has developed a proprietary miniprotein radioconjugate platform that selectively delivers radioisotopes to targeted tumors, maximizing anti-cancer activity while minimizing exposure to normal tissues [4] - The company’s pipeline includes AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, with potential applications across various tumor types [5]

Core Insights - Artiva Biotherapeutics has appointed Thad Huston as Chief Financial Officer, bringing extensive experience in capital allocation and operational execution to support the company's growth in cell therapies for autoimmune diseases and cancers [1][2]. Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing safe and effective cell therapies for patients with autoimmune diseases and cancers [1][6]. - The company's lead program, AlloNK, is an allogeneic NK cell therapy designed to enhance the efficacy of monoclonal antibodies for B-cell depletion [6]. Leadership Appointment - Thad Huston has over 30 years of global leadership experience in finance, commercial strategy, and operations within the pharmaceuticals and biotechnology sectors [2]. - Huston previously served as CFO and COO at Galapagos, leading the company's transition to an oncology-focused cell therapy organization [2]. Inducement Grant - Artiva's Board of Directors approved an employment inducement grant of 220,000 restricted stock units to Mr. Huston, which will vest over four years [3][4]. - The grant is contingent upon the filing of a registration statement to register the shares under Artiva's 2025 Inducement Plan [4][5]. Clinical Development - AlloNK is currently being evaluated in three clinical trials targeting B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren's disease [6]. - The company is preparing to receive feedback from the FDA regarding a potential pivotal trial and plans to share clinical efficacy data in rheumatoid arthritis in the first half of the year [2]. Strategic Positioning - Artiva aims to position itself for sustained growth by leveraging Huston's financial discipline and operational rigor as it approaches key clinical and regulatory milestones [2].

Company strengthens industry-leading compliance program with new per-transaction identity verification procedure, enhancing protections against Crypto ATM fraudATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bitcoin Depot (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced it has initiated a phased rollout of a new compliance enhancement requiring customers to provide identification for every transaction at its kiosks, strengthening the Company’s safeguards again ...

KUALA LUMPUR, Malaysia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sagtec Global Limited (NASDAQ: SAGT), an AI-native enterprise SaaS provider, today announced a major strategic evolution of its technology stack: the deployment of an Agentic AI Orchestration Layer. This transition moves SAGT beyond traditional SaaS toward a fully Autonomous Agent model, designed to maximize AI ROI for its 12,000+ business clients. Following the success of its recent US$4.0 million Smart AI mobility contract, Sagtec is now integratin ...

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will parti ...

Core Viewpoint - Rogers Communications is launching satellite-powered asset tracking technology in partnership with Geotab, marking it as the first Canadian wireless carrier to offer satellite-to-mobile service for IoT applications [1][2]. Group 1: Service Launch and Features - The new service, named GO Anywhere Plus, allows businesses to track critical assets like trailers and equipment across Canada, even in areas lacking traditional cell coverage [2][3]. - This service utilizes low-earth orbit (LEO) satellites and Rogers' national wireless spectrum, enabling seamless switching between the wireless network and satellite service for IoT devices [4]. Group 2: Market Context and Applications - Given Canada's vast geography and resource-based economy, the satellite tracking capability is expected to enhance uptime, logistics, and delivery of essential equipment [3]. - Applications for this technology include fleet and asset tracking along remote highways and rail corridors, as well as powering automated sensors in industries such as forestry and mining [3]. Group 3: Partnership and Impact - The collaboration between Rogers and Geotab aims to provide Canadian businesses with reliable asset tracking solutions, especially in remote areas where traditional cellular networks are insufficient [4]. - Only 18% of Canada is covered by traditional wireless networks, highlighting the significance of this new satellite service in expanding connectivity [4].

SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ten-League International Holdings Limited (Nasdaq: TLIH) (the “Company” or “Ten-League”), a Singapore-based provider of turnkey project solutions, is pleased to announce the following financial guidance for Fiscal Year 2025. Fiscal Year 2025 refers to the 12-month period beginning on January 1, 2025, and ending on December 31, 2025. Net revenue is expected to be in the range of S$75.0 million (US$58.3 million) to S$76.0 million (US$59.1 million), representing an ...

First-of-its-kind partnership designed to educate and mobilize patients to imagine a healthier tomorrowDAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: ARDX), a biopharmaceutical company with a vision of creating a healthier tomorrow for patients, today announced a multi-year partnership naming Ardelyx as an official corporate pharmaceutical Marketing Partner of the LPGA Tour. The exclusive partnership unites two o ...

PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the News ...

SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via ...